Avantor, Inc. (NYSE:AVTR) Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio lowered its position in Avantor, Inc. (NYSE:AVTR - Free Report) by 32.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 233,005 shares of the company's stock after selling 113,817 shares during the period. Public Employees Retirement System of Ohio's holdings in Avantor were worth $4,909,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in AVTR. Dodge & Cox lifted its stake in Avantor by 44.9% in the fourth quarter. Dodge & Cox now owns 99,145,770 shares of the company's stock worth $2,089,001,000 after purchasing an additional 30,727,673 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC lifted its stake in shares of Avantor by 41.4% during the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 30,528,092 shares of the company's stock worth $643,227,000 after acquiring an additional 8,936,879 shares during the last quarter. Norges Bank bought a new stake in shares of Avantor during the 4th quarter worth approximately $142,512,000. The Manufacturers Life Insurance Company lifted its position in shares of Avantor by 48.3% during the fourth quarter. The Manufacturers Life Insurance Company now owns 9,158,175 shares of the company's stock worth $192,963,000 after purchasing an additional 2,983,439 shares during the last quarter. Finally, Clarkston Capital Partners LLC lifted its position in shares of Avantor by 43.6% during the fourth quarter. Clarkston Capital Partners LLC now owns 8,145,825 shares of the company's stock worth $171,633,000 after purchasing an additional 2,473,395 shares during the last quarter. Institutional investors own 95.08% of the company's stock.

Insider Transactions at Avantor

In other Avantor news, Director Joseph R. Massaro purchased 8,100 shares of Avantor stock in a transaction dated Tuesday, April 29th. The shares were acquired at an average cost of $12.30 per share, with a total value of $99,630.00. Following the completion of the transaction, the director now owns 35,038 shares in the company, valued at approximately $430,967.40. This trade represents a 30.07% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Gregory L. Summe purchased 30,000 shares of Avantor stock in a transaction dated Friday, May 23rd. The shares were acquired at an average cost of $12.50 per share, for a total transaction of $375,000.00. Following the completion of the transaction, the director now owns 100,000 shares of the company's stock, valued at approximately $1,250,000. This represents a 42.86% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders purchased 83,100 shares of company stock valued at $1,027,630. Corporate insiders own 1.20% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on AVTR. Citigroup decreased their target price on Avantor from $22.00 to $18.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. TD Cowen lowered shares of Avantor from a "buy" rating to a "hold" rating and set a $15.50 price objective for the company. in a report on Monday, April 28th. Morgan Stanley lowered shares of Avantor from an "overweight" rating to an "equal weight" rating in a report on Tuesday, April 29th. Robert W. Baird decreased their price target on shares of Avantor from $21.00 to $17.00 and set an "outperform" rating for the company in a research note on Monday, April 28th. Finally, The Goldman Sachs Group downgraded shares of Avantor from a "buy" rating to a "neutral" rating and decreased their price target for the company from $23.00 to $14.00 in a research note on Tuesday, April 29th. Seven research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $18.88.

Avantor Stock Up 0.4%

NYSE:AVTR traded up $0.05 during trading hours on Monday, reaching $12.96. The company's stock had a trading volume of 11,182,093 shares, compared to its average volume of 7,971,848. The company has a market capitalization of $8.83 billion, a P/E ratio of 12.46, a price-to-earnings-growth ratio of 1.55 and a beta of 1.09. Avantor, Inc. has a 12 month low of $11.82 and a 12 month high of $28.00. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.70 and a current ratio of 1.07. The stock has a 50 day moving average price of $14.01 and a two-hundred day moving average price of $17.85.

Avantor (NYSE:AVTR - Get Free Report) last issued its quarterly earnings data on Friday, April 25th. The company reported $0.23 EPS for the quarter, hitting analysts' consensus estimates of $0.23. The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.61 billion. Avantor had a net margin of 10.49% and a return on equity of 12.17%. Avantor's revenue for the quarter was down 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.22 earnings per share. Equities analysts predict that Avantor, Inc. will post 1.06 EPS for the current fiscal year.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.